GlassScriptPhysician profile
Stephen C Hammack
NPI 1639396393
$7,718.44
in general payments reported to CMS, 2019-2025
35 companies · $1,445 in 2025
The $1,445 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,028 · 2020: $1,001 · 2021: $819 · 2022: $760 · 2023: $1,279 · 2024: $1,385 · 2025: $1,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,060 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,059.73 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,429.09 | 2019-2025 | |
| Abbvie INC. | $1,235.02 | 2019-2025 | |
| Novo Nordisk INC | $913.20 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $596.59 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $571.85 | 2019-2025 | Arexvy, Shingrix, Boostrix |
| Amgen INC. | $352.07 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbott Laboratories | $297.65 | 2021-2025 | Freestyle Libre 2, Proclaim, Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $271.73 | 2019-2024 | Breztri, Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $246.19 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $239.60 | 2019-2025 | Ofev, Jardiance |
| Novartis Pharmaceuticals Corporation | $185.12 | 2019-2024 | |
| Inspire Medical Systems, INC. | $169.96 | 2023-2025 | Inspire |
| Lundbeck LLC | $140.94 | 2023-2024 | Vyepti |
| Merck Sharp & Dohme LLC | $116.67 | 2020-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astellas Pharma US INC | $93.33 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $88.00 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.83 | 2019-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $73.73 | 2019-2023 | |
| Currax Pharmaceuticals LLC | $67.94 | 2023 | Nexletol, Onzetra Xsail, Nexlizet |
| Phathom Pharmaceuticals, INC. | $67.23 | 2024-2025 | Voquezna |
| Allergan, INC. | $58.30 | 2020 | |
| Supernus Pharmaceuticals, INC. | $56.56 | 2020-2025 | Qelbree |
| Bayer Healthcare Pharmaceuticals INC. | $52.58 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $44.83 | 2020-2025 | Austedo Xr |
| Exact Sciences Corporation | $44.04 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.58 | 2024-2025 | Caplyta |
| Inari Medical, INC. | $34.44 | 2024-2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $28.34 | 2019-2024 | Trintellix |
| Boston Scientific Corporation | $20.07 | 2025 | Wavewriter Alpha Prime 16 |
| Mylan Specialty L.P. | $19.13 | 2019 | |
| Corium, LLC | $18.89 | 2025 | Azstarys |
| Ironwood Pharmaceuticals, INC | $16.88 | 2023 | Linzess |
| Alnylam Pharmaceuticals INC. | $15.33 | 2025 | Givlaari |
| E.R. Squibb & Sons, L.L.C. | $14.67 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Hammack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.